查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602778

驱虫药市场：按药物类别、给药途径、目标病原体、应用、分销管道 - 全球预测 2025-2030

Anthelmintic Drugs Market by Drug Class (Benzimidazoles, Piperazine), Route of Administration (Injectable, Oral), Target Pathogen, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年驱虫药市值为33亿美元，预计2024年将达35.7亿美元，复合年增长率为8.02%，预计2030年将达到56.8亿美元。

驱虫药对于治疗寄生虫引起的感染疾病至关重要，在维护公共卫生和兽医领域中发挥重要作用。这些药物的使用范围扩大到预防和治疗血吸虫病、丝虫病和其他影响人类和动物的寄生虫相关疾病。由于全球旅行的增加、不受管制地使用会滋生抗药性细菌的市售驱虫药物以及人们对动物保健重要性的认识的提高，对这些药物的需求进一步增加。主要用于农业和人类医疗保健设施，应用范围从大规模驱虫计划到常规兽医实践。最终用户包括医院、诊所、製药公司和畜牧业。

主要市场统计
基准年[2023] 33亿美元
预计年份 [2024] 35.7亿美元
预测年份 [2030] 56.8亿美元
复合年增长率（%） 8.02%

市场成长受到蠕虫感染疾病增加、提高疗效的药物配方进步以及主要企业之间为扩大市场而建立的策略联盟等因素的影响。最近的市场状况有利于新兴市场的创新给药方法和配方，驱虫正成为公共卫生政策的重要组成部分。扩大服务范围并提高意识可以显着提高市场渗透率。然而，挑战依然存在，包括日益增长的抗药性威胁、严格的监管政策以及限制新药开发和采用的潜在副作用。

创新的时机尤其成熟，例如开发具有低抗药性的频谱驱虫药和针对特定地区寄生虫的药物。同样重要的是要关注在不影响疗效的情况下减少给药频率的研究。市场的性质要求在研究和监管方面投入大量资金，要求企业专注于策略伙伴关係和持续创新。透过投资加强分子研究和生物资讯学，公司可以预测抗药性模式并提供解决方案来满足新兴需求。市场成功的关键在于平衡技术创新与严格遵守和预测市场需求。

市场动态：揭示快速发展的驱虫药市场的关键市场洞察

供需的动态交互作用正在改变驱虫药市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 随着人们对维护动物健康的兴趣日益浓厚，养宠物的数量也不断增加。
    • 增加动物保健和健康支出
    • 蠕虫感染疾病的加速流行
  • 市场限制因素
    • 抗寄生虫药物高成本
  • 市场机会
    • 增加动物保健服务中心
    • 驱虫药作为癌症免疫调节剂的出现
  • 市场挑战
    • 对抗药性的担忧

波特五力：驾驭驱虫药市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解驱虫药市场的外部影响

外部宏观环境因素在塑造驱虫药市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解驱虫药市场竞争状况

对驱虫药市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵驱虫药市场供应商绩效评估

FPNV定位矩阵是评估驱虫药市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了驱虫药市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，驱虫药市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 宠物拥有量的增加和对动物保护的兴趣日益浓厚

健康

      • 增加动物保健和健康支出
      • 加速寄生虫感染疾病的传播
    • 抑制因素
      • 驱虫药高成本
    • 机会
      • 增加兽医保健服务中心
      • 驱虫药作为癌症免疫调节剂的出现
    • 任务
      • 对产生抗药性的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的驱虫药市场

  • 苯并咪唑酮
  • Piperazine

第七章驱虫药市场：依给药途径

  • 可注射的
  • 口服

第八章以目标病原体分類的驱虫药市场

  • 十二指肠钩虫
  • 蛔虫
  • 蛲虫
  • 鞭虫

第九章驱虫药市场：依应用分类

  • 动物
  • 人类
    • 胃肠道感染疾病
    • 实质神经囊虫病

第十章驱虫药市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房
  • 动物医院/诊所
  • 兽医药房

第十一章美洲驱虫药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太驱虫药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲/中东/非洲驱虫药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Aden Healthcare
  • Anikem Laboratories
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Cipla Limited
  • Dechra Pharmaceuticals PLC
  • Dr.Reddys Laboratories Inc.
  • Edenbridge Pharmaceuticals LLC
  • GlaxoSmithKline PLC
  • Green Cross Remedies
  • Healthy Life Pharma Private Limited
  • Johnson & Johnson Services, Inc.
  • Kosher Pharmaceuticals
  • Lineage Therapeutics Inc
  • Lupin Limited
  • Mankind Pharma Ltd.
  • McKesson Corporation
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Novartis AG
  • Sankur Pharmaceuticals Pvt. Ltd
  • Takeda Pharmaceutical Company Limited
  • Virbac SA
Product Code: MRR-FB6C9E792F81

The Anthelmintic Drugs Market was valued at USD 3.30 billion in 2023, expected to reach USD 3.57 billion in 2024, and is projected to grow at a CAGR of 8.02%, to USD 5.68 billion by 2030.

Anthelmintic drugs, essential in treating infections caused by parasitic worms, serve a crucial role in maintaining public health and veterinary sectors. The scope of these drugs encompasses the prevention and treatment of diseases like schistosomiasis, filariasis, and other worm-related conditions affecting both humans and animals. The necessity for these drugs is accentuated by increasing global travel, unregulated use of over-the-counter anthelmintics fostering resistance, and the growing awareness of the importance of animal healthcare. Used predominantly in the agricultural industry and human healthcare facilities, their application ranges from large-scale deworming programs to routine veterinary practices. End-users include hospitals, clinics, pharmaceutical companies, and animal husbandry operations.

KEY MARKET STATISTICS
Base Year [2023] USD 3.30 billion
Estimated Year [2024] USD 3.57 billion
Forecast Year [2030] USD 5.68 billion
CAGR (%) 8.02%

Market growth is influenced by factors such as rising incidences of helminthic infections, advancements in drug formulations enhancing efficacy, and strategic collaborations among key players for market expansion. Recent opportunities lie in emerging markets where deworming is becoming an integral part of public health policies, presenting a lucrative landscape for innovative delivery methods and formulations. Extending the outreach to underserved regions and enhancing awareness could significantly boost market penetration. However, challenges persist, including the growing threat of drug resistance, stringent regulatory policies, and potential side effects constraining the development and adoption of new drugs.

The landscape is ripe for innovation, particularly in developing broad-spectrum anthelmintics with reduced resistance tendencies and drugs tailored to specific regional parasites. Emphasizing research that reduces dosage frequency without compromising effectiveness will also be critical. The nature of the market is characterized by substantial research and regulatory investment, requiring businesses to focus on strategic partnerships and continuous innovation. By investing in enhanced molecular research and bioinformatics, companies can anticipate resistance patterns and tailor solutions to meet emerging needs. The key to market success lies in balancing innovation with stringent compliance and market need anticipation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anthelmintic Drugs Market

The Anthelmintic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing pet adoption coupled with rising focus towards maintaining animal health
    • Increasing spending for animal healthcare and wellness
    • Accelerating prevalence of helminthic infections
  • Market Restraints
    • High cost of antiparasitic drugs
  • Market Opportunities
    • Increasing veterinary healthcare services centers
    • Emergence of anthelmintic drugs as immune modulators in cancer
  • Market Challenges
    • Concerns about the development of drug resistance

Porter's Five Forces: A Strategic Tool for Navigating the Anthelmintic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anthelmintic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anthelmintic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anthelmintic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anthelmintic Drugs Market

A detailed market share analysis in the Anthelmintic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anthelmintic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anthelmintic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anthelmintic Drugs Market

A strategic analysis of the Anthelmintic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anthelmintic Drugs Market, highlighting leading vendors and their innovative profiles. These include Aden Healthcare, Anikem Laboratories, Bayer AG, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Cipla Limited, Dechra Pharmaceuticals PLC, Dr.Reddys Laboratories Inc., Edenbridge Pharmaceuticals LLC, GlaxoSmithKline PLC, Green Cross Remedies, Healthy Life Pharma Private Limited, Johnson & Johnson Services, Inc., Kosher Pharmaceuticals, Lineage Therapeutics Inc, Lupin Limited, Mankind Pharma Ltd., McKesson Corporation, Merck & Co., Inc., Norbrook Laboratories Limited, Novartis AG, Sankur Pharmaceuticals Pvt. Ltd, Takeda Pharmaceutical Company Limited, and Virbac S.A..

Market Segmentation & Coverage

This research report categorizes the Anthelmintic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Benzimidazoles and Piperazine.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Target Pathogen, market is studied across Ancylostoma Duodenale, Ascaris Lumbricoides, Enterobius Vermicularis, and Trichuris Trichiura.
  • Based on Application, market is studied across Animal and Human. The Human is further studied across Gastrointestinal Infections and Parenchymal Neurocysticercosis.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Veterinary Hospitals & Clinics, and Veterinary Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing pet adoption coupled with rising focus towards maintaining animal

health

      • 5.1.1.2. Increasing spending for animal healthcare and wellness
      • 5.1.1.3. Accelerating prevalence of helminthic infections
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of antiparasitic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing veterinary healthcare services centers
      • 5.1.3.2. Emergence of anthelmintic drugs as immune modulators in cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns about the development of drug resistance
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anthelmintic Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Benzimidazoles
  • 6.3. Piperazine

7. Anthelmintic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Anthelmintic Drugs Market, by Target Pathogen

  • 8.1. Introduction
  • 8.2. Ancylostoma Duodenale
  • 8.3. Ascaris Lumbricoides
  • 8.4. Enterobius Vermicularis
  • 8.5. Trichuris Trichiura

9. Anthelmintic Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Animal
  • 9.3. Human
    • 9.3.1. Gastrointestinal Infections
    • 9.3.2. Parenchymal Neurocysticercosis

10. Anthelmintic Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies
  • 10.5. Veterinary Hospitals & Clinics
  • 10.6. Veterinary Pharmacies

11. Americas Anthelmintic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anthelmintic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anthelmintic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aden Healthcare
  • 2. Anikem Laboratories
  • 3. Bayer AG
  • 4. Boehringer Ingelheim International GmbH
  • 5. Ceva Sante Animale
  • 6. Cipla Limited
  • 7. Dechra Pharmaceuticals PLC
  • 8. Dr.Reddys Laboratories Inc.
  • 9. Edenbridge Pharmaceuticals LLC
  • 10. GlaxoSmithKline PLC
  • 11. Green Cross Remedies
  • 12. Healthy Life Pharma Private Limited
  • 13. Johnson & Johnson Services, Inc.
  • 14. Kosher Pharmaceuticals
  • 15. Lineage Therapeutics Inc
  • 16. Lupin Limited
  • 17. Mankind Pharma Ltd.
  • 18. McKesson Corporation
  • 19. Merck & Co., Inc.
  • 20. Norbrook Laboratories Limited
  • 21. Novartis AG
  • 22. Sankur Pharmaceuticals Pvt. Ltd
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Virbac S.A.

LIST OF FIGURES

  • FIGURE 1. ANTHELMINTIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTHELMINTIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTHELMINTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTHELMINTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTHELMINTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTHELMINTIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PIPERAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANCYLOSTOMA DUODENALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ASCARIS LUMBRICOIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ENTEROBIUS VERMICULARIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TRICHURIS TRICHIURA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENCHYMAL NEUROCYSTICERCOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. ANTHELMINTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 281. ANTHELMINTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023